Back

Ocugen doses first patient in Phase 3 OCU410 gene-therapy trial

Verifying
  • Ocugen announced dosing the first patient in its Phase 3 OCU410 trial.
  • The trial evaluates OCU410 modifier gene therapy for geographic atrophy.
  • The condition is secondary to dry age-related macular degeneration, according to Ocugen.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.